Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency.
Autosomal recessive interleukin-1 receptor-associated kinase (IRAK)-4 and myeloid differentiation factor (MyD)88 deficiencies impair Toll-like receptor (TLR)- and interleukin-1 receptor-mediated immunity. We documented the clinical features and outcome of 48 patients with IRAK-4 deficiency and 12 pa...
| প্রধান লেখক: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| বিন্যাস: | Journal article |
| ভাষা: | English |
| প্রকাশিত: |
2010
|
| _version_ | 1826263438631895040 |
|---|---|
| author | Picard, C von Bernuth, H Ghandil, P Chrabieh, M Levy, O Arkwright, P McDonald, D Geha, R Takada, H Krause, J Creech, C Ku, C Ehl, S Maródi, L Al-Muhsen, S Al-Hajjar, S Al-Ghonaium, A Day-Good, N Holland, S Gallin, J Chapel, H Speert, D Rodriguez-Gallego, C Colino, E Garty, B |
| author_facet | Picard, C von Bernuth, H Ghandil, P Chrabieh, M Levy, O Arkwright, P McDonald, D Geha, R Takada, H Krause, J Creech, C Ku, C Ehl, S Maródi, L Al-Muhsen, S Al-Hajjar, S Al-Ghonaium, A Day-Good, N Holland, S Gallin, J Chapel, H Speert, D Rodriguez-Gallego, C Colino, E Garty, B |
| author_sort | Picard, C |
| collection | OXFORD |
| description | Autosomal recessive interleukin-1 receptor-associated kinase (IRAK)-4 and myeloid differentiation factor (MyD)88 deficiencies impair Toll-like receptor (TLR)- and interleukin-1 receptor-mediated immunity. We documented the clinical features and outcome of 48 patients with IRAK-4 deficiency and 12 patients with MyD88 deficiency, from 37 kindreds in 15 countries.The clinical features of IRAK-4 and MyD88 deficiency were indistinguishable. There were no severe viral, parasitic, and fungal diseases, and the range of bacterial infections was narrow. Noninvasive bacterial infections occurred in 52 patients, with a high incidence of infections of the upper respiratory tract and the skin, mostly caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively. The leading threat was invasive pneumococcal disease, documented in 41 patients (68%) and causing 72 documented invasive infections (52.2%). P. aeruginosa and Staph. aureus documented invasive infections also occurred (16.7% and 16%, respectively, in 13 and 13 patients, respectively). Systemic signs of inflammation were usually weak or delayed. The first invasive infection occurred before the age of 2 years in 53 (88.3%) and in the neonatal period in 19 (32.7%) patients. Multiple or recurrent invasive infections were observed in most survivors (n = 36/50, 72%).Clinical outcome was poor, with 24 deaths, in 10 cases during the first invasive episode and in 16 cases of invasive pneumococcal disease. However, no death and invasive infectious disease were reported in patients after the age of 8 years and 14 years, respectively. Antibiotic prophylaxis (n = 34), antipneumococcal vaccination (n = 31), and/or IgG infusion (n = 19), when instituted, had a beneficial impact on patients until the teenage years, with no seemingly detectable impact thereafter.IRAK-4 and MyD88 deficiencies predispose patients to recurrent life-threatening bacterial diseases, such as invasive pneumococcal disease in particular, in infancy and early childhood, with weak signs of inflammation. Patients and families should be informed of the risk of developing life-threatening infections; empiric antibacterial treatment and immediate medical consultation are strongly recommended in cases of suspected infection or moderate fever. Prophylactic measures in childhood are beneficial, until spontaneous improvement occurs in adolescence. |
| first_indexed | 2024-03-06T19:51:46Z |
| format | Journal article |
| id | oxford-uuid:243269db-143a-47e4-8eb0-01321487f61b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:51:46Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:243269db-143a-47e4-8eb0-01321487f61b2022-03-26T11:48:44ZClinical features and outcome of patients with IRAK-4 and MyD88 deficiency.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:243269db-143a-47e4-8eb0-01321487f61bEnglishSymplectic Elements at Oxford2010Picard, Cvon Bernuth, HGhandil, PChrabieh, MLevy, OArkwright, PMcDonald, DGeha, RTakada, HKrause, JCreech, CKu, CEhl, SMaródi, LAl-Muhsen, SAl-Hajjar, SAl-Ghonaium, ADay-Good, NHolland, SGallin, JChapel, HSpeert, DRodriguez-Gallego, CColino, EGarty, BAutosomal recessive interleukin-1 receptor-associated kinase (IRAK)-4 and myeloid differentiation factor (MyD)88 deficiencies impair Toll-like receptor (TLR)- and interleukin-1 receptor-mediated immunity. We documented the clinical features and outcome of 48 patients with IRAK-4 deficiency and 12 patients with MyD88 deficiency, from 37 kindreds in 15 countries.The clinical features of IRAK-4 and MyD88 deficiency were indistinguishable. There were no severe viral, parasitic, and fungal diseases, and the range of bacterial infections was narrow. Noninvasive bacterial infections occurred in 52 patients, with a high incidence of infections of the upper respiratory tract and the skin, mostly caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively. The leading threat was invasive pneumococcal disease, documented in 41 patients (68%) and causing 72 documented invasive infections (52.2%). P. aeruginosa and Staph. aureus documented invasive infections also occurred (16.7% and 16%, respectively, in 13 and 13 patients, respectively). Systemic signs of inflammation were usually weak or delayed. The first invasive infection occurred before the age of 2 years in 53 (88.3%) and in the neonatal period in 19 (32.7%) patients. Multiple or recurrent invasive infections were observed in most survivors (n = 36/50, 72%).Clinical outcome was poor, with 24 deaths, in 10 cases during the first invasive episode and in 16 cases of invasive pneumococcal disease. However, no death and invasive infectious disease were reported in patients after the age of 8 years and 14 years, respectively. Antibiotic prophylaxis (n = 34), antipneumococcal vaccination (n = 31), and/or IgG infusion (n = 19), when instituted, had a beneficial impact on patients until the teenage years, with no seemingly detectable impact thereafter.IRAK-4 and MyD88 deficiencies predispose patients to recurrent life-threatening bacterial diseases, such as invasive pneumococcal disease in particular, in infancy and early childhood, with weak signs of inflammation. Patients and families should be informed of the risk of developing life-threatening infections; empiric antibacterial treatment and immediate medical consultation are strongly recommended in cases of suspected infection or moderate fever. Prophylactic measures in childhood are beneficial, until spontaneous improvement occurs in adolescence. |
| spellingShingle | Picard, C von Bernuth, H Ghandil, P Chrabieh, M Levy, O Arkwright, P McDonald, D Geha, R Takada, H Krause, J Creech, C Ku, C Ehl, S Maródi, L Al-Muhsen, S Al-Hajjar, S Al-Ghonaium, A Day-Good, N Holland, S Gallin, J Chapel, H Speert, D Rodriguez-Gallego, C Colino, E Garty, B Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. |
| title | Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. |
| title_full | Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. |
| title_fullStr | Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. |
| title_full_unstemmed | Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. |
| title_short | Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. |
| title_sort | clinical features and outcome of patients with irak 4 and myd88 deficiency |
| work_keys_str_mv | AT picardc clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT vonbernuthh clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT ghandilp clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT chrabiehm clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT levyo clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT arkwrightp clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT mcdonaldd clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT gehar clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT takadah clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT krausej clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT creechc clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT kuc clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT ehls clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT marodil clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT almuhsens clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT alhajjars clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT alghonaiuma clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT daygoodn clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT hollands clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT gallinj clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT chapelh clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT speertd clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT rodriguezgallegoc clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT colinoe clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency AT gartyb clinicalfeaturesandoutcomeofpatientswithirak4andmyd88deficiency |